

Amid Uncertain U.S. Markets, German Fund Offers Sound Investment.

Print

Date: Oct 10, 2008

Words: 401

Publication: PR Newswire

BOSTON, Oct. 10 /PRNewswire/ -- As global financial markets continue to suffer from the unpredictable and unstable economic worldwide crisis, institutional investors are looking closely at a German venture capital fund that projects significantly higher returns than traditional equities.

Innoveas AG (<http://www.innoveas.com/>) specializes in commercializing intellectual property originating from Germany's top universities, with a goal of establishing a diversified portfolio focusing on technology. Many major corporate brands began in the laboratories of German research institutions.

"Innoveas has long-standing relationships with some of the best universities and research centers in Germany, which turned research into the personal computer, the MP3 player and countless other technological advances that are indispensable in today's world," said Innoveas CEO Armin J. Lang. "Given the instability the markets have felt over the last few weeks, and are expected to continue for several months, the most savvy long-term investors know that research-backed innovation is one of the most attractive alternative investments."

Lang is currently in the United States meeting with institutional investors, and has been heartened by the reception Innoveas' fund has received.

"We're meeting with some of the country's most knowledgeable investors, and the feedback we're getting is amazingly positive," Lang said. "They know this is the time to look at alternative investments, as traditional funds and equities are taking a beating. What does surprise them is learning so much of the products that have made American companies thrive actually were invented in Germany. And that excites them to get in on the ground floor of the next massive technological advancement."

Innoveas AG's first fund, the M.O.R.E. (Money Out of Research Excellence) Fund will total euro 50 million, and will close in 2009.

M.O.R.E. identifies, develops, and invests in early-stage science and technology with the potential to become leading commercial enterprises in the German economy and abroad. The current portfolio includes 10 companies with room for an additional 15 companies by the end of 2009. The current portfolio, built on the best of German scientific research and technological innovation, includes companies like Albutech (blood filters for liver disease treatment), ARTCline (new diagnosis and therapy for sepsis), Materion (nanosensors for hydrogen detection), Neuroproof (drug screening with neuronal cells on chip), and Tridelity Display Solutions (autostereoscopic 3D-flatscreens).

CONTACT: Thomas Lee, 451 Marketing

(617) 259-1605

CONTACT: Thomas Lee of 451 Marketing for Innoveas AG, +1-617-259-1605

Web site: <http://www.innoveas.com/>

COPYRIGHT 2008 PR Newswire Association LLC

Copyright 2008 Gale, Cengage Learning. All rights reserved.